共 85 条
[1]
Alunno A(2019)Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent Cells. 8 898-2337
[2]
Padjen I(2017)Pathogenetic insights from the treatment of rheumatoid arthritis Lancet. 389 2328-ii115
[3]
Fanouriakis A(2013)Janus kinase inhibitors in autoimmune diseases Ann Rheum Dis 72 ii111-40
[4]
Boumpas DT(2019)Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis Mod Rheumatol 29 31-26
[5]
McInnes IB(2016)2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis Arthritis Rheumatol. 68 1-699
[6]
Schett G(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis 79 685-i26
[7]
O'Shea J(2019)Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis Rheumatology (Oxford) 58 i17-i42
[8]
Kontzias A(2019)Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis Rheumatology (Oxford) 58 i34-29
[9]
Yamaoka K(2018)Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-week, randomized, single-blind, extension study Mod Rheumatol 28 20-2866
[10]
Tanaka Y(2016)Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study Arthritis Res Ther 18 34-2877